Cantor sees favorable Tourette’s readout for Neurocrine by end of year

Cantor Fitzgerald analyst Charles Duncan believes the T-Force Gold study benefits from the past experience Neurocrine Biosciences has in Tourette’s syndrome. The study will read out as “interpretable, and favorable” by the end of 2018 to support a supplemental new drug application possibly in the first half of 2019, Duncan tells investors in a research note. The analyst keeps an Overweight rating on Neurocrine with a $150 price target.
https://thefly.com/landingPageNews.php?id=2790519

STAAR Surgical price target raised to $55 from $43 at Canaccord

Canaccord analyst Jason Mills raised his price target to $55 from $43 following the FDA approval of its Toric ICL. The analyst said it represent tangible progress for the company along the path of tapping into the U.S. refractive market and could also serve as upside to current guidance. Mills reiterated his Buy rating on STAAR Surgical shares.
https://thefly.com/landingPageNews.php?id=2790541

BioTelemetry price target raised to $66 from $57 at Raymond James

Raymond James analyst Jayson Bedford raised Outperform rated Bio Telemetry’s price target to $66 from $57 saying the seamless integration of the Lifewatch acquisition combined with new product introductions has increased growth and driven improved visibility.
https://thefly.com/landingPageNews.php?id=2790549

Arrowhead price target raised to $24 from $20 at Jefferies

Jefferies analyst Maury Raycroft raised his price target for Arrowhead Pharmaceuticals to $24 after the company last week reported initial ARO-HBV data at the World Gastroenterologists Summit. The update was unexpected and an early glimpse into what should be a more mature, robust dataset at the American Association for the Study of Liver Diseases meeting, Raycroft tells investors in a research note. He sees the de-risking as a positive and keeps a Buy rating on Arrowhead.
https://thefly.com/landingPageNews.php?id=2790555

Global Blood shares have ‘significant upside’ into end of 2018, says Nomura

After attending the Annual Sickle Cell Disease Therapeutics Conference, hosted by Global Blood Therapeutics, Nomura Instinet analyst Christopher Marai has a strengthened view that a voxelotor new drug application submission will occur by the end of 2018. Further, the company will likely receive accelerated approval based on data to date, Marai tells investors in a research note. The analyst recommends buying shares of Global Blood and believes the recent pullback is “unfounded” on the back of key takeaways from the SCD conference. He sees “significant upside” for the shares into a year-end NDA submission. Marai keeps a Buy rating on Global Blood Therapeutics with a $109 price target.
https://thefly.com/landingPageNews.php?id=2790563

Allergan to host medical aesthetics day

Medical Aesthetics Day to be held in New York on September 14 a 9 am. Weblink: https://www.allergan.com/investors/events-presentations.aspx
https://thefly.com/landingPageNews.php?id=2787979

Aptinyx to present NYX-2925 data for chronic pain at IASP

Aptinyx announced the presentation of two posters highlighting preclinical data on novel N-methyl D-aspartate, or NMDA, receptor modulator, NYX-2925, that support its ongoing clinical development for the treatment of chronic pain conditions. Results from the preclinical studies will be presented at the International Association for the Study of Pain’s, or IASP. NYX-2925 has demonstrated activity in preclinical models of numerous neuropathic pain conditions with a favorable tolerability profile. In a Phase 1 clinical study in healthy human subjects, NYX-2925 was well tolerated across a wide dose range, including dose levels well in excess of the expected therapeutic levels. NYX-2925 is currently in Phase 2 clinical development for the treatment of painful diabetic peripheral neuropathy, or DPN, and is also being evaluated in an exploratory Phase 2 study in fibromyalgia. The FDA has granted fast track designation to Aptinyx’s development of NYX-2925 for the treatment of neuropathic pain associated with DPN.
https://thefly.com/landingPageNews.php?id=2790613